
Vitamin C enhances skin health by promoting epidermal cell growth and regeneration, offering a potential solution for aging and thinning skin.

Kennedy Ferruggia is an assistant editor at Pharmacy Times®. She graduated from The College of New Jersey in 2023 in journalism and marketing. Prior to this position, she worked as a pharmacy associate for community pharmacies.

Vitamin C enhances skin health by promoting epidermal cell growth and regeneration, offering a potential solution for aging and thinning skin.

The injection is indicated for the treatment of sepsis and other serious infections, enhancing treatment efficiency and patient care.

A low-fat vegan diet reduces dietary acid load and promotes weight loss more effectively than a Mediterranean diet.

Obecabtagene autoleucel shows promising efficacy and safety in treating relapsed/refractory B-ALL, benefiting patients of all ages, including older adults.

A direct link between memories and physical changes has not yet been established.

Pharmacists and clinicians collaborate to carefully manage rilonacept therapy.

A recent study reveals high RSV antibody levels in older adults, highlighting the importance of vaccination and natural infection for enhanced immunity.


A groundbreaking trial shows zimislecel significantly reduces insulin dependence in patients with type 1 diabetes, offering hope for a functional cure.

New research reveals that combining bimagrumab and semaglutide enhances fat loss while preserving muscle mass, revolutionizing obesity treatment strategies.

Low-energy total diet replacement programs show promise for individuals with obesity and type 2 diabetes, without increasing eating disorder risks.

The session highlighted tirzepatide’s unique mechanism of action, based on comprehensive clinical data and real-world evidence.

Continuous glucose monitoring (CGM) is poised to transform type 2 diabetes management.

Ready-to-use glucagon simplifies hypoglycemia rescue by providing easy-to-use options for patients and caregivers.

Continuous glucose monitors provide individuals with type 2 diabetes with real-time, actionable insights about their health.

Oral semaglutide shows promising cardiovascular benefits for type 2 diabetes patients, reducing major adverse events by 14% in the SOUL trial.

CagriSema shows promising weight loss and metabolic benefits in recent trials, offering new hope for obesity and type 2 diabetes management.

Experts discuss the low prescription rates of ready-to-use glucagon for individuals with diabetes.

Expert shares insights on advancing diabetes care in community pharmacies.

Semaglutide shows promise in enhancing walking ability and reducing disease progression in patients with type 2 diabetes and peripheral artery disease.

The expert discusses the evolving landscape of diabetes treatment, emphasizing the importance of comprehensive care beyond glucose management.

Expert shares key upcoming sessions at the American Diabetes Association 85th Scientific Sessions.

New research highlights the significant health risks of respiratory syncytial virus (RSV) in older adults, emphasizing the need for effective vaccines and public health strategies.

Combining omega-3 supplements with exercise enhances immune response and alleviates tooth infections, offering new insights into managing apical periodontitis.

New research reveals a significant link between type 2 diabetes, obesity, and fatty liver disease.

The FDA approves garadacimab-gxii, a treatment for hereditary angioedema (HAE), offering convenient monthly self-injections for patients 12 years and older.

Eli Lilly is expanding access to tirzepatide, a groundbreaking GLP-1 medication for weight management, offering more affordable options for obesity treatment.

Discover the latest FDA-approved treatments, including Dupixent for chronic urticaria and Valtoco for seizure clusters, enhancing patient care options.

Nemolizumab shows promising long-term efficacy in reducing itch and skin lesions for atopic dermatitis, enhancing quality of life for patients.

Moderna's mRNA-1345 vaccine gains FDA approval, enhancing protection against RSV for high-risk adults aged 18 to 59 years, following earlier approvals for older populations.